Amicus Therapeutics Inc

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. Its commercial product and product candidates include Galafold, an orally administered monotherapy for adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a two-component treatment program for adults with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 in a pivotal Phase 3 study for focal segmental glomerulosclerosis (FSGS) kidney disease. The company has collaboration and license agreements with GlaxoSmithKline for Galafold and with Dimerix Limited for DMX-200. Incorporated in 2002 and headquartered in Princeton, New Jersey, Amicus Therapeutics, Inc. has operated as a subsidiary of BioMarin Pharmaceutical Inc. since April 27, 2026.